Applied therapeutics granted fast track designation by fda for at-007 for galactosemia

New york, june 17, 2021 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the u.s. food and drug administration (fda) has granted fast track designation to at-007 for the treatment of galactosemia, a rare metabolic disease. at-007 is the company's central nervous system-penetrant aldose reductase inhibitor in development for multiple rare metabolic disorders, including galactosemia, sord and pmm2-cdg.
APLT Ratings Summary
APLT Quant Ranking